Document is current
Any future updates will be listed below
-
Authors
Hassan, Ahmed N. https://orcid.org/0000-0003-0115-1858
Agabani, Zena
Ferkul, Sean
Minami, Osamu
Le Foll, Bernard
Ahmed, Clara
Bormann, Jill
-
Funding
Funding for this research was provided by:
Innovation fund of the alternative funding plan for the academic Health Sciences of Ontario (2021)
- License Information
-
More Information
Article History
Accepted: 24 October 2024
First Online: 12 November 2024
Declarations
:
: Informed consent was obtained from all participants and this study was approved by the Centre for Addiction and Mental Health (CAMH’s) research ethics board (018–2019).
: Informed consent was obtained from all individual participants included in the study.
: Financial interests: Dr. Bernard Le Foll received funding (grand awards and salary support) from Pfizer Inc. for investigator-initiated projects. He received funding from Indivior for a sponsored clinical trial. He has in-kind donations of cannabis products from Aurora Cannabis Enterprises Inc., nabixomols donation from GW Pharmaceuticals (funded by CIHR and NIH), and study medication donations from Pfizer Inc. and Bioprojet Pharma. Also, he obtained a coil for a transcranial magnetic stimulation (TMS) study from Brainsway. Dr. Le Foll received industry funding (research grants) from Canopy Growth Corporation, Bioprojet Pharma, Alcohol Countermeasure Systems (ACS), Alkermes, and Universal Ibogaine.Non-financial interests: He has participated in the National Advisory Board Meeting (Emerging Trends BUP-XR) for Indivior Canada and has been consultant for Shinogi.
: Artificial intelligence was not used.
